RYTM — Rhythm Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $2.46bn
- $2.29bn
- $77.43m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 14.48 | ||
| Price to Tang. Book | 15.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 31.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -66.42% | ||
| Return on Equity | -85.1% | ||
| Operating Margin | -238.1% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 3.15 | 23.64 | 77.43 | 133.03 | 207.54 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). It is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.
Directors
- David Meeker CHM (66)
- Hunter Smith CFO (53)
- Pamela Cramer CHO
- Jennifer Chien EVP (46)
- Yann Mazabraud EVP (48)
- William Roberts CAO (42)
- Linda Manning OTH
- Edward Mathers LED (61)
- Jennifer Good DRC (56)
- Stuart Arbuckle IND (55)
- Camille Bedrosian IND (68)
- Christophe Jean IND (65)
- David McGirr IND (66)
- Lynn Tetrault IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 26th, 2013
- Public Since
- October 5th, 2017
- No. of Shareholders
- 17
- No. of Employees
- 226
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 60,963,518
- Address
- 222 Berkeley Street, 12th Floor Boston, BOSTON, 02116
- Web
- http://www.rhythmtx.com
- Phone
- +1 8572644280
- Contact
- Hannah Deresiewicz
- Auditors
- Ernst & Young LLP
Upcoming Events for RYTM
Rhythm Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Rhythm Pharmaceuticals Inc Earnings Release
Similar to RYTM
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Rhythm Pharmaceuticals share price?
As of Today at 19:18 UTC, shares in Rhythm Pharmaceuticals are trading at $40.33. This share price information is delayed by 15 minutes.
How has the Rhythm Pharmaceuticals share price performed this year?
Shares in Rhythm Pharmaceuticals last closed at $40.33 and the price had moved by +108.75% over the past 365 days. In terms of relative price strength the Rhythm Pharmaceuticals share price has outperformed the S&P500 Index by +68.58% over the past year.
What are the analyst and broker recommendations for Rhythm Pharmaceuticals?
The overall consensus recommendation for Rhythm Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Rhythm Pharmaceuticals dividend yield?
Rhythm Pharmaceuticals does not currently pay a dividend.
Does Rhythm Pharmaceuticals pay a dividend?
Rhythm Pharmaceuticals does not currently pay a dividend.
When does Rhythm Pharmaceuticals next pay dividends?
Rhythm Pharmaceuticals does not currently pay a dividend.
How do I buy Rhythm Pharmaceuticals shares?
To buy shares in Rhythm Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Rhythm Pharmaceuticals?
As of the previous close price of $40.33, shares in Rhythm Pharmaceuticals had a market capitalisation of $2.46bn.
Where are Rhythm Pharmaceuticals shares listed?
Here are the trading details for Rhythm Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: RYTM
What kind of share is Rhythm Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Rhythm Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Rhythm Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Rhythm Pharmaceuticals is $58.89. That is 46.02% above the last closing price of $40.33.
Analysts covering Rhythm Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$4.14 for the next financial year.
What is the trend in the Rhythm Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rhythm Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +37.82%.
As of the last closing price of $40.33, shares in Rhythm Pharmaceuticals were trading +23.46% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Rhythm Pharmaceuticals PE Ratio?
The Rhythm Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $40.33.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals' management team is headed by:
- David Meeker - CHM
- Hunter Smith - CFO
- Pamela Cramer - CHO
- Jennifer Chien - EVP
- Yann Mazabraud - EVP
- William Roberts - CAO
- Linda Manning - OTH
- Edward Mathers - LED
- Jennifer Good - DRC
- Stuart Arbuckle - IND
- Camille Bedrosian - IND
- Christophe Jean - IND
- David McGirr - IND
- Lynn Tetrault - IND